RE:RE:Here is a quote from Heineman (ONC/Y Chief Medical Officer)"GOBLET's interim results indicate pelareorep may be the key to finally improving the standard-of-care for first-line treatment of pancreatic cancer, a clear need given that treatment options have not changed for many years despite their limited benefits," commented Thomas C. Heineman, M.D., Ph.D., Chief Medical Officer of Oncolytics Biotech Inc.
https://www.biospace.com/article/releases/oncolytics-biotech-presents-updated-clinical-data-at-sitc-annual-meeting-showing-a-69-percent-objective-response-rate-and-confirmed-complete-response-in-goblet-study-s-pancreatic-cancer-cohort/